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Summary
Background The beneficial effects of statins are probably
not exclusively related to lipid lowering activity. Therefore,
we investigated the effect of simvastatin on blood pressure
and heart rate variability (HRV), which can be used for
studying autonomous nervous system activity.
Material and methods In a prospective, placebo-control-
led, crossover trial, we studied 9 males and 11 females aged
55.2 ± 9.7 years with hypercholesterolemia (TC > 220
mg/dl), and normal blood pressure or essential hyperten-
sion stage 1–2. After 4 weeks of dietary modifications and
placebo administration all subjects were given 20 mg of
simvastatin for 4 weeks, followed by a placebo for another
4 weeks. Office and 24-h blood pressure (ABPM), the bio-
chemical parameters of neuroendocrine function and HRV
were evaluated. Time-domain and frequency-domain vari-
ables were studied such as: SDNN, r-MSSD, pNN50, TP,
HF, LF and LF/HF ratio.
Results All subjects had significant decrease in total and
LDL-cholesterol as well as triglycerides. However, four
weeks of simvastatin was not associated with a significant
change in office or ambulatory blood pressure. Treatment
did not affect basal or stimulated plasma levels of
catecholamines, aldosterone, cortisol, neuropeptide Y,
renin activity. The differences in HRV between groups did
not reach statistical significance. No significant correlation
between changes in serum lipid levels and change in car-
diac autonomic indices was found.
Conclusions This short, prospective, cross-over study has
not shown significant effects of simvastatin on blood pres-
sure, biochemical parameters of neuroendocrine function
and heart rate variability (HRV) parameters in patients
with hypercholesterolemia with or without hypertension.
key words: hypercholesterolemia, blood pressure, heart
rate variability, HMG-CoA reductase inhibitors
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Background
In many large, controlled, clinical trials, statins —
HMG-CoA reductase inhibitors, have proved to re-
duce cholesterol synthesis effectively and decrease the
risk of cardiovascular events [1, 2]. The benefits of
statin therapy cannot be fully explained on the basis
of a reduction in plasma cholesterol levels and addi-
tional mechanisms have been suggested [3]. Since
HMG-CoA reductase inhibitors can restore endothe-
lial function [4], their influence on blood pressure
has been analysed in several animal and human stu-
dies with conflicting results. Glorioso et al. [5], in
a double-blind, placebo-controlled trial, described
a significant decrease in both systolic and diastolic
blood pressure in patients with hypertension and hy-
percholesterolemia treated with pravastatin. In earli-
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er, open-label studies, authors [6] showed that the
addition of a statin to existing anti-hypertensive treat-
ment improved blood pressure control. Another
group of researchers, found a decrease in systolic
blood pressure in normotensive subjects with hyper-
cholesterolemia treated with statin, with most of the
reduction in the first month of treatment [7]. In an-
other study, adding simvastatin to antihypertensive
treatment decreased blood pressure [8]. Moreover,
therapy with HMG-CoA reductase inhibitors diminis-
hed blood pressure response to mental stress [9] and
norepinephrine or angiotensin II infusion [10] in pa-
tients with hypercholesterolemia and hypertension.
However, in another study, there was no difference
in both systolic and diastolic blood pressure in pa-
tients treated with statin added to antihypertensive
therapy [11].
Therefore, we planned a placebo-controlled, cross-
over trial to evaluate the effect of simvastatin —
a natural HMG-CoA reductase inhibitor, on blood
pressure in hypertensive and normotensive subjects
with hypercholesterolemia. To investigate the poten-
tial mechanisms of the effects of statin, we assessed
basal and stimulated levels of various biochemical
parameters reflecting neuroendocrine activity. Addi-
tionally, we used heart rate variability (HRV) to study
the sympathetic and parasympathetic function of the
autonomic nervous system in the patients.
The autonomic nervous system plays an impor-
tant role in blood pressure regulation [11, 12]. Spec-
tral analysis of HRV can be used to assess the impact
of sympathetic and parasympathetic influences on
the cardiovascular system [12, 13]. In several studies
abnormalities of HRV analysis in hypertension have
been found [14–17]. HRV measurements are nonin-
vasive, have good reproducibility if used under stan-
dardised conditions [18–20]. Basically, HRV can be
assessed in two ways: by calculation of indices based
on statistical operations on R-R intervals (time do-
main analysis ) [21] or by spectral (frequency domain)
analysis of an array of R-R intervals [22] Analy-
sis can be performed on 24-hour ECG recordings.
Material and methods
Subjects
We studied 9 males and 11 females aged 55.2 ±
± 9.7 years (range: 29–71) with hypercholesterolemia
(fasting total plasma cholesterol level > 220 mg/
/dl), divided into 2 groups according to blood pressure
level. Subjects with essential hypertension (HTN) had
diastolic blood pressure > 90 mm Hg and < 110 mm
Hg, and systolic blood pressure > 140 mm Hg and
< 180 mm Hg. Subjects were included in the nor-
motensive group (NT) if each reading of their blood
pressure was below 140 mm Hg systolic and
90 mm Hg diastolic. Blood pressure was measured
with the patient in a seated position between 8 and
10 a.m. by a physician. Four consecutive measure-
ments were taken over a 10 minute period with
a mercury sphygmomanometer, and the average of
the last 3 values taken was used.
The exclusion criteria were as follows: an eleva-
tion of serum transaminases or creatine phosphoki-
nase, a diagnosis of kidney disease, diabetes mellitus,
a history of myopathies, unstable angina, congestive
heart failure, any other severe condition with a poor
prognosis. Women with child-bearing potential,
nursing or pregnant women were excluded. None of
the subjects had been treated previously with lipid-
-lowering drugs.
The protocol was approved by the Ethical Com-
mittee of the Medical University of Warsaw. All sub-
jects gave their written informed consent to partici-
pate in the study.
Study protocol
A total of 20 participants meeting these criteria
were enrolled into a four week run-in phase of the
study. During this period they received dietary advice
and were given a placebo between 7 and 9 p.m. each
day. The patients had been counselled on the diet by
a study physician and a diet program which paralleled
the dietary recommendations of the American Heart
Association (AHA) was implemented [23]. No lipid
lowering and hypotensive drugs were allowed
throughout the entire run-in phase. Compliance with
the study protocol was assessed by a pill-count (100 ¥
number of pills taken/number of pills prescribed) and
an interview every 4 weeks. Three subjects did not
complete the study due to withdrawal of consent or
unsatisfactory compliance (less than 80%).
At the end of the run-in phase 17 participants
(8 normotensives, 9 hypertensives) had met the in-
clusion criteria. Their data are presented in Table I.
On the following visit (week 0) an office blood pres-
sure, 24-h ambulatory blood pressure measurements
(ABPM), and heart rate variability (HRV) measure-
ments were performed. Daily urine was collected and
fasting blood samples were drawn by venipuncture
between 8 and 10 a.m., plasma was separated imme-
diately and stored at –70°C until it was assayed. From
then on, all subjects were given 20 mg of simvastatin
(Zacar, provided by MSD Polska, Warsaw, Poland)
between 7 and 9 p.m. every day for 4 weeks. After
completion of this period of the study, simvastatin
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was replaced with a placebo for another 4 weeks. Sub-
jects were investigated on each visit after the run-in
phase (week 0), after 4 weeks on simvastatin (week
4) and 4 weeks of crossover treatment with a placebo
(week 8). Studies included a medical history and
physical examination, office and ABPM blood pres-
sure, HRV, blood and daily urine collection. Plasma
levels of epinephrine (E), norepinephrine (NE), neu-
ropeptide Y (NPY), were measured at rest and after
stimulation. Blood samples were drawn after 30 minu-
tes of rest in the recumbent position. Then subjects
were kept standing for 8 minutes and blood was col-
lected again.
Laboratory measurements
Plasma total (TC) and HDL cholesterol, trigly-
cerides, electrolytes, creatinine, creatine phosphoki-
nase, creatine phosphokinase-MB, aspartate ami-
notransferase, alanine aminotranspherase, were
measured using routine biochemical methods. LDL-
-cholesterol was determined by means of Friedewald
formula. Plasma norepinephrine and epinephrine
concentrations were determined by high performance
liquid chromatography (HPLC, Bio-Rad). Nore-
pinephrine and epinephrine in urine were measured
by the fluorometric method of Anton et al. [24], and
urinary metanephrines colorimetrically [25].
Plasma renin activity, aldosterone, cortisol and neu-
ropeptide Y were determined by means of a radio-
immunoassay (RIA).
Twenty-four hour blood pressure monitoring
(ABPM) was performed with a Space Labs 90207
monitor (Redmont, Washington, USA). Readings
were obtained every 15 minutes during the day (06:00
to 23:00) and every 20 minutes at night (23:00 to
06:00).
24-hour ECG recordings were performed on the
Medilog Excel 2 System (Oxford Instruments Ltd.,
Abington, Oxon, UK) and were processed for HRV
analysis. Ambulatory data were recorded on standard
cassette tapes with the use of Oxford 4000 series re-
corders. The fast Fourier transform was then calcu-
lated.
The time-domain variables measured were as fol-
lows: the standard deviation of normal RR intervals
(SDNN), the percentage of differences between ad-
jacent normal RR intervals > 50 ms (pNN50), the
square root of the mean of squared differences be-
tween adjacent normal RR intervals (r-MSSD).
The frequency domain variables included as fol-
lows: total power (TP, 0.00–0.50 Hz), high frequen-
cy power (HF, 0.15–0.40 Hz), low frequency power
(LF, 0.04–0.15 Hz), and LF/HF ratio.
Statistics
The study was a prospective, cross-over without
blinding for simvastatin. Data presented as a mean
± SD. The Mann-Whitney rank-sum test, and
Wilcoxon signed-rank test for paired data were
used in analysing the data as appropriate. The
Spearman correlation was employed to study the
relationship between cholesterol lowering and
blood pressure levels. P values less than 0.05 were
considered statistically significant.
Table I. Baseline characteristics of subjects studied
Parameters Hypertension Without hypertension p value
n = 9 n = 8 (Mann-Whitney U test)
Age (years) 56±7 55± 8 0.73
Gender (male/female)                             6M/3F                                  2M/6F
SBP [mm Hg] 154.8±10 125.1± 8 < 0.01
DBP [mm Hg] 97.7±4 80.1± 4 < 0.01
Pulse pressure [mm Hg] 50.6±7 44.6± 6 0.13
24-hour SBP [mm Hg] 136.7±9 117.9± 8 < 0.01
24-hour DBP [mm Hg] 86±5 72.2± 3 < 0.01
Total cholesterol [mg/dl] 226.7±35 241± 28 0.52
LDL cholesterol [mg/dl] 139.6±30 152.6± 17 0.40
HDL cholesterol [mg/dl] 46.38±9.47 53± 10.52 0.15
Triglycerides [mg/dl] 207.6±88 194.1± 96 0.83
Norepinephrine [ng/ml] 227.6±55 247.1± 2 0.84
Epinephrine [ng/ml] 28.7±12 20.9± 43 0.28
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Results
Effect of simvastatin therapy on plasma lipid
concentration
All subjects who completed 4 weeks of simvastatin
therapy showed a significant decrease in both total and
LDL-cholesterol levels. TC was reduced by 26.7% and
LDL-cholesterol by 43.9% in normotensive subjects,
and by 30.1% and 38.4% in hypertensives, respectively.
In both groups, triglycerides plasma levels at week
4 were lower as compared to week 0, and these differ-
ences reached the level of statistical significance in both
groups of subjects. Plasma concentration of HDL-cho-
lesterol did not change during the simvastatin treat-
ment phase. After switching to a placebo, both total
and LDL-cholesterol as well as TG levels returned to
pretreatment values (tab. II).
Effect of simvastatin therapy on blood pressure
After 4 weeks of the run-in phase, subjects assigned
to the HTN group had higher ABPM values as com-
pared to normotensive subjects, which remained sig-
nificantly different throughout all the study periods. In
hypertensives, 4 weeks of simvastatin administration
were not associated with a significant change in the
parameters estimated in ABPM such as: mean 24-hour,
day or night systolic and diastolic blood pressure. These
values did not change when patients were switched to
a placebo. Similarly, mean values for these parameters
were not different in normotensive subjects during vi-
sits at weeks 0, 4 and 8. In the course of simvastatin
Table II. The effect of simvastatin treatment on blood pressure and biochemical parameters of
neuroendocrine activity in subjects with hypercholesterolemia and normal blood pressure
Parameters HL week 0 HL week 4 HL week 8 p value
Wilcoxon test
SBP [mm Hg] 125.1 ± 8 120 ± 11 123.3 ± 7 0.17
DBP [mm Hg] 80.1 ± 4 78.2 ± 5 79 ± 4 0.62
Pulse pressure [mm Hg] 44.6 ± 6 41 ± 6 42.6 ± 5 0.15
24-hour SBP [mm Hg] 117.9 ± 8 113 ± 9.5 115 ± 7 0.86
24-hour DBP [mm Hg] 72.2 ± 3 72 ± 4 71.7 ± 3 0.34
Total cholesterol [mg/dl] 241 ± 28 176.6 ± 19* 225.1 ± 36 0.01
LDL cholesterol [mg/dl] 152.6 ± 17 94 ± 14* 137 ± 30 0.02
Triglycerides [mg/dl] 194.1 ± 96 139.9 ± 37* 195 ± 136 0.04
HDL cholesterol [mg/dl] 53 ± 10,5 54.6 ± 13.2 53 ± 13 0.17
Norepinephrine [ng/ml]
0 min 247.1 ± 92.6 225 ± 164 271 ± 142 0.40
8 min 463.7 ± 112.4 466.6 ± 231 541 ± 300.4 0.88
Epinephrine [ng/ml]
0 min 20,9 ± 2.5 22.2 ± 18.3 20.6 ± 15.4 1.00
8 min 43.1 ± 25 39 ± 28 33 ± 24 0.26
Neuropeptide Y [pg/ml]
0 min 5.2 ± 1.7 5.6 ± 2.5 5.8 ± 2.6 0.67
8 min 6.0 ± 1.1 5.6 ± 1.7 6.3 ± 2.5 0.48
Metanephrines [µg/24h] 559,4 ± 229 597 ± 182 530 ± 167 0.67
Norepinephrine [µg/24h] 17.8 ± 10.6 16 ± 4.6 12.6 ± 2.4 0.78
Epinephrine [µg/24h] 3.4 ± 0.8 2.3 ± 0.9 2.4 ± 2 0.12
Aldosterone [ng/dl] 4.7 ± 2.3 4.5 ± 1.3 5.2 ± 3 0.49
Plasma renin activity [ng/ml/h] 0.9 ± 0.3 0.8 ± 0.6 0.8 ± 0.6 0.67
Fibrinogen [mg/dl] 292.5 ± 10 338.6 ± 34 320 ± 64* 0.03
Cortisol [µg/dl] 9.2 ± 1.8 9.5 ± 4.9 9 ± 4.4 0.78
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administration, we observed a decrease in the office
systolic blood pressure in 5 patients, and diastolic blood
pressure in 4 subjects in the group of 8 normotensives
with hypercholesterolemia. Among 9 hypertensive pa-
tients a small decrease in office systolic or diastolic
blood pressure was noted in 3 and 5 patients, respec-
tively. However, these changes were not paralleled in
ABPM. Changes in the concentration of total choles-
terol and LDL-cholesterol did not correlate with
changes in the mean blood pressure (24-hour, day or
night) calculated from ABPM in both groups studied.
Effect of simvastatin on biochemical parameters
of neuroendocrine function
After run-in phase (week 0) plasma levels of epine-
phrine and norepinephrine and urinary excretion of
native catecholamines and their major metabolite did
not differ between normotensive and hypertensive
subjects. With patients remaining in the upright po-
sition, stimulated plasma concentrations of epine-
phrine and norepinephrine were similar in hyper-
tensive and normotensive patients. An increase in
plasma catecholamines levels was not affected by sim-
vastatin therapy. Also, no significant change in plas-
ma levels of neuropeptide Y, aldosterone, cortisol and
plasma renin activity was observed.
Effect of simvastatin therapy on heart rate
variability (HRV) parameters
All HRV parameters, except of the LF/HF ratio, were
lower in patients with hypertension when compared
with normotensive subjects (tab. IV). However, the dif-
ferences were not statistically significant. In persons with
normal blood pressure, treatment with simvastatin led
Table III. The effect of simvastatin treatment on blood pressure and biochemical parameters of
neuroendocrine activity in subjects with hypercholesterolemia and hypertension
Parameters HTN week 0 HTN week 4 HTN week 8 p value
Wilcoxon test
SBP [mm Hg] 154.8 ± 10 155.7 ± 12 154.6 ± 11 0.67
DBP [mm Hg] 97.7 ± 4 98.7 ± 7 96.5 ± 5 0.68
Pulse pressure [mm Hg] 50.6 ± 7 53 ± 9 51 ± 8 0.07
24-hour SBP [mm Hg] 136.7 ± 9 139.8 ± 14 136.9 ± 12 0.26
24-hour DBP [mm Hg] 86 ± 5 86.8 ± 8 85.9 ± 7 0.37
Total cholesterol [mg/dl] 226.7 ± 35 158.4 ± 33* 224.9 ± 42 0.01
LDL cholesterol [mg/dl] 139.6 ± 30 78.3 ± 22* 135.7 ± 40 0.02
Triglycerides [mg/dl] 207.6 ± 88 180 ± 93* 204.2 ± 96 0.04
HDL cholesterol [mg/dl] 46.4 ± 9.5 48.3 ± 10 47 ± 9.8 0.09
Norepinephrine [ng/ml]
0 min 227.6 ± 55 223 ± 67 238 ± 65 0.78
8 min 445.3 ± 89 445 ± 52 507.6 ± 161 1.00
Epinephrine [ng/ml]
0 min 28.7 ± 12 20 ± 8 19 ± 8 0.26
8 min 43.3 ± 21 36 ± 7 31 ± 19 0.48
Neuropeptide Y [pg/ml]
0 min 8.1 ± 9 6.7 ± 8 7.1 ± 6 0.21
8 min 7.5 ± 8.2 7.1 ± 6.2 8.4 ± 7.2 0.51
Metanephrines [µg/24h] 563 ± 213 565 ± 182 514 ± 177.2 0.34
Norepinephrine [µg/24h] 21.3 ± 4.5 21.4 ± 4 13.6 ± 3.2 0.68
Epinephrine [µg/24h] 2.77 ± 1.2 2.8 ± 0.5 2.0 ± 1 0.22
Aldosterone [ng/dl] 4.4 ± 1.7 4.8 ± 1.4 4.5 ± 1.4 0.61
Plasma renin activity [ng/ml/h] 0.8 ± 0.2 0.8 ± 1.4 1.0 ± 0.4 0.68
Fibrinogen [mg/dl] 243 ± 45 269 ± 61 275 ± 20.6 0.39
Cortisol [µg/dl] 7.3 ± 3.6 8.1 ± 2.6 7.9 ± 3 0.78
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Table IV. HRV parameters in subjects with hypercholesterolemia and normal blood pressure
or with hypertension
Parameters Without hypertension Hypertension p value
n = 8 n = 9 (Mann-Whitney U test)
SDNN [ms] 131.9 ± 35 120.3 ± 36 0.74
r-MSSD [ms] 46.14 ± 37 24.9 ± 14 0.25
PNN50 [ms] 3.95 ± 4 1.4 ± 1 0.44
LF [ms2] 486.9 ± 353 287.8 ± 164 0.27
HF [ms2] 188.8 ± 215 69.4 ± 51 0.22
TP [ms2] 1677.7 ± 992 1270.4 ± 577 0.40
LF/HF 3.66 ± 1.8 4.4 ± 1 0.25
Table V. The effect of simvastatin treatment on HRV parameters in subjects with hyperchole-
sterolemia and normal blood pressure
Parameters HL week 0 HL week 4 HL week 8 p value
Wilcoxon test
SDNN [ms] 131.9 ± 35 120.2 ± 29 141.6 ± 54 0.28
r-MSSD [ms] 46.14 ± 37 28 ± 19 54.8 ± 50 0.14
PNN50 [ms] 3.95 ± 4 4.92 ± 6.4 7.7 ± 8 0.46
LF [ms2] 486.9 ± 353 561 ± 499 705.3 ± 639 0.71
HF [ms2] 188.8 ± 215 219.8 ± 309 355.4 ± 378 0.46
TP [ms2] 1677.7 ± 992 1892.2 ± 1469 2319.3 ± 1700 0.14
LF/HF 3.66 ± 1.8 3.2 ± 1.09 2.2 ± 0.4 0.71
Table VI. The effect of simvastatin treatment on HRV parameters in subjects with hyperchole-
sterolemia and hypertension
Parameters HTN week 0 HTN week 4 HTN week 8 p value
Wilcoxon test
SDNN [ms] 120.3 ± 36 124.2 ± 40 121.1 ± 57 0.24
r-MSSD [ms] 24.9 ± 14 42.6 ± 33 32.8 ± 25 0.13
PNN50 [ms] 1.4 ± 1 1.3 ± 1 3.02 ± 2 0.73
LF [ms2] 287.8 ± 164 297.6 ± 124 396.8 ± 269 0.31
HF [ms2] 69.4 ± 51 69.3 ± 32 104.7 ± 44 0.61
TP [ms2] 1270.4 ± 577 1337.7 ± 523 1577.1 ± 1088 0.61
LF/HF 4.4 ± 1 4.63 ± 1.5 3.7 ± 1.4 0.17
to an increase in the time-domain parameter pNN50
and all frequency parameters (LF, HF, TP), except
LF/HF. Hypertensive patients showed an increase
in all parameters after simvastatin treatment. In both
groups these changes did not reach statistical signifi-
cance. Moreover, there was a further increase in most
of the parameters in the following weeks with a pla-
cebo. These changes might be attributed to the rela-
tively high variabilities in HRV parameters among
the patients.
Discussion
In our small group of patients, therapy with
HMG-CoA reductase inhibitor, simvastatin, did not
nadciśnienie tętnicze rok 2006, tom 10, nr 3
186 www.nt.viamedica.pl
influence blood pressure levels. There was no effect
of simvastatin on blood pressure in subjects with hy-
percholestorolemia, both normotensive and hyper-
tensive. All subjects had a satisfactory response to hy-
polipemic therapy and during the end of the active
treatment period serum levels of total and LDL cho-
lesterol decreased significantly by 26.7% and 43.9%,
respectively in normotensive patients and by 30.1%
and 38.4% in those who were hypertensive. These
results are similar to the reported efficacy of simva-
statin, which also allows one to assume good compli-
ance with the experimental protocol.
In a similar, placebo-controlled study, Glorioso et.
al. [5] described decreases in systolic and diastolic
blood pressures by 8 and 5 mm Hg in 25 subjects
treated with pravastatin for 16 weeks. The authors
noted a significant decrease in diastolic blood pres-
sure after 4 weeks of therapy but for systolic blood
pressure, the difference between the HMG-CoA re-
ductase inhibitor and the placebo reached statistical
significance after 12 weeks of therapy. However, in
our study we could not detect any significant change
in blood pressure after 4 weeks of administration of
simvastatin as compared to pretreatment placebo. In
the above-mentioned study with pravastatin, systolic
blood pressure decreased in 23 subjects and diastolic
pressure in 22 subjects who were among 25 patients
who received pravastatin therapy compared to a pre-
treatment placebo. In a small open label study, Abe-
tel et al. described the hypotensive effect of fluvasta-
tin in 12 out of 23 treated patients with hypertension
and hypercholesterolemia [26].
In our study, simvastatin treatment was followed
by a similar period of placebo administration to in-
vestigate if any changes in blood pressure might be
associated with treatment with HMG-CoA redu-
ctase inhibitors. We found a decrease in office systol-
ic or diastolic blood pressure in some hypertensive
patients and normotensive subjects during HMG-
CoA therapy, but in subjects who experienced a
marked lowering of blood pressure during statin ad-
ministration, replacement of simvastatin with a pla-
cebo was not associated with a tendency to elevate
blood pressure. These changes were not associated
with similar differences in mean values of blood
pressure obtained during 24-hour measurements.
Thus, in our study, they may represent variations in
blood pressure levels obtained during standard con-
ditions in a clinical setting.
It is possible that extending the period of HMG-
-CoA administration in our study could have induced
significant changes in blood pressure values. In other
studies which have reported a significant hypotensive
effect of statin treatment, a significant lowering of
blood pressure was noted after about 4 weeks of ad-
ministration of HMG-CoA reductase inhibitor and
continued to decrease during treatment [8, 9]. More-
over, the number of patients included in our study
could be too low to find any potential effect of the
treatment on blood pressure. Glorioso et al. [5] were
able to detect a significant reduction in blood pressure,
studying a group of 25 patients. We investigated, alto-
gether, 17 subjects and could not observe any tendency
towards reduction in blood pressure while an expected
lowering of blood cholesterol was noted. In our study
four weeks of simvastatin therapy decreased total and
LDL-cholesterol by 30.1% and 43.9% in hypertensive
subjects, respectively. Glorioso et al. after 16 weeks of
administration of pravastatin described a decrease in
the total cholesterol level by 17% and LDL cholesterol
by 25%. This was accompanied by a reduction of systo-
lic and diastolic blood pressure by 8 and 5 mm Hg as
compared to the baseline. Many epidemiological stu-
dies have found a positive relationship between
cholesterol levels and blood pressure [27–30]. This as-
sociation may be due to common risk factors (age,
obesity, dietary habits) related to increases in both cho-
lesterol and blood pressure. However, results of The
Tromso Study [27] suggest that there are biological
interrelations (i.e. similar causative factors like hyper-
insulinism) between blood pressure and atherogenic
blood lipid fractions. Therefore, one might expect
a reduction of blood pressure due to a lowering of blood
lipid levels by itself. Despite a consistent decrease in
the serum concentration of cholesterol we did not ob-
serve similar changes in blood pressure. In the studies
which reported a significant reduction of blood pres-
sure during treatment with HMG-CoA reductase in-
hibitors, there was no association between blood pres-
sure and serum cholesterol levels [5, 26]. Moreover,
our results did not show any correlation between se-
rum cholesterol levels (basal or degree of reduction
during therapy) and blood pressure changes. These
findings suggest that potential hypotensive effect of
statins is not related to lipid-lowering. Possible mech-
anisms might include decreased NO availability [31,
32], vessel wall reactivity to pressor agents [33], chang-
es in endothelin production [34] or an anti-prolifera-
tive effect on vascular smooth muscle cells [35].
We measured the synthesis of epinephrine, nore-
pinephrine and their major metabolites both in basal
and stimulated conditions during a postural test. The
activation of an adrenergic response during the pos-
tural test resulted in doubled plasma levels of epine-
phrine and norepinephrine, but there were no differ-
ences in their levels during simvastatin treatment as
compared to placebo period. Other authors have
shown that 3 weeks of therapy with pravastatin re-
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duced diastolic blood pressure response to the infu-
sion of norepinephrine and angiotensin II [10]. In
a study, which included 14 patients with mild hyper-
tension and hypercholesterolemia, Straznicky et al.
observed a trend of lower diastolic responses to iso-
metric exercise, although without reaching a statisti-
cally significant difference [10]. It is interesting that
in their study there was no difference in systolic and
diastolic blood pressure after 3 weeks of pravastatin
or a placebo. In another study, 6 weeks of lovastatin
therapy modified blood pressure response to psycho-
logical stress [9] and the authors noted a significant
correlation between total plasma cholesterol concen-
tration and changes in systolic blood pressure.
A reduction in plasma aldosterone with statins re-
ported by others [36] may have also played a role in
decreasing blood pressure. In our study, plasma al-
dosterone and cortisol levels were not significantly
correlated with blood pressure changes and were not
affected by simvastatin therapy. The lack of effect of
HMG-CoA reductase inhibitors on adrenal hor-
mones has also been reported by others [37].
Animal studies on the effect of HMG-CoA reduct-
ase inhibitors on blood pressure has provided con-
flicting results. Some investigators have found de-
creased systemic blood pressure in spontaneously hy-
pertensive rats (SHR) [33] as well as in mineralocor-
ticoid-induced hypertension (DOCA-salt) [38]. In
contrast to these studies, Roullet et al. [39, 40] found
that inhibitors of HMG-CoA reductase increased the
responses of resistance vessels to pressor substances
and raised blood pressure in SHR. They also de-
scribed similar phenomenon in human arterial seg-
ments isolated from subcutaneous fat tissue [41]. The
authors suggest that HMG-CoA reductase inhibitors
decrease the synthesis of farnesol which blocks the
L-type voltage dependent calcium channel. Other
studies in both animals and humans showed an acti-
vation of endothelial isoform of nitric oxide syn-
thetase (ecNOS, NOS-3) with simultaneous im-
provement of vasodilatatory endothelial function.
The augmentation of both basal and stimulated NO
production was observed as soon as after 1 month of
treatment with simvastatin, although no effect on sys-
temic blood pressure was noted even after 3 months
of administration [4]. In large, multicentre trials
which included a substantial number of patients with
hypertension, no effect of HMG-CoA reductase in-
hibitors on blood pressure was reported. However,
these studies were not designed to test the influence
of statin on blood pressure and hypertensive patients
were treated to obtain satisfactory blood pressure con-
trol. If HMG-CoA reductase inhibitors possessed
a significant ability to reduce blood pressure, the
number of hypotensive medications would have had
to be lower in a group assigned to a cholesterol-low-
ering regimen. None of such data are available from
completed large trials [1, 42–44]. In small, open label
study, Sposito et al. [8] described a reduction in blood
pressure in patients with hypertension when HMG
CoA reductase inhibitor was included into hypoten-
sive regimen.
In essential hypertension, an enhanced sympathet-
ic activity and a reduced vagal activity have been
found by a heart rate variability (HRV) analysis. The
altered sympathovagal balance of cardiac control re-
sults in less vagally mediated respiratory sinus arrhyth-
mia and more baroreflex-related heart rate varia-
bility in patients with essential hypertension com-
pared with normotensive controls. A reduced day-
night oscillation in sympathetic activity is also found
in these patients. Some investigators reported a nega-
tive correlation between the extent of coronary athero-
sclerosis and respiratory sinus arrhythmia measured
by spectral analysis in patients who had coronary ar-
tery angiography. HRV can be used to quantify the
effects of drugs on the autonomic nervous system. It
has been used to investigate the mode of action of
drugs in adults. The effects of some drugs on HRV
have been studied in hypertensive patients [45]. With
spectral analysis it is possible to unravel and quantitate
sympathetic and parasympathetic activities of drugs
and might give more information about their effects in
cardiac diseases. Some agents with well-established
roles in the treatment of cardiovascular diseases are
able to restore the sympathetic-parasympathetic ba-
lance.
In our study there were lower baseline HRV pa-
rameters in patients with hypertension but these
changes were not statistically significant. In the work
of Singh et al. from the Framingham Heart Study,
a low frequency parameter (LF) was associated with
new-onset hypertension in men [46]. The researchers
found a relationship between this parameter and the
incidence of hypertension in men. The relationship
was weaker in women and for diastolic rather than
systolic blood pressure. The impact of LF on blood
pressure was studied. A decrease in LF was associated
with an increase in systolic and diastolic blood pres-
sure [33]. An association of another HRV component
i.e. HF with hypertension has also been reported [34].
Some methodological aspects may have played role in
the differences between these two studies.
Furberg has suggested that certain statins may dif-
fer, particularly in their activities not associated with
any lipid-lowering potential [47]. Glorioso et al. [5] in
their study, described a marked reduction in blood
pressure during treatment with pravastatin. Due to
nadciśnienie tętnicze rok 2006, tom 10, nr 3
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fewer lipophilic properties related to its open lactone
ring chemical structure, pravastatin reaches much
higher plasma concentrations that other statins and
may raise its potential to interact with endothelial cells
[32]. Despite the lower ability of simvastatin to acti-
vate ecNOS in cultured endothelial cells as compared
to pravastatin, both statins improve endothelial func-
tion in subjects with hypercholesterolemia [4, 32].
Conclusions
This short, prospective, cross-over study did not
reveal any significant effects of simvastatin on blood
pressure, biochemical parameters of neurocrine func-
tion and heart rate variability components in patients
with hypercholesterolemia with or without hyperten-
sion. The role of HRV beyond the inspection of pa-
tients after myocardial infarction and diabetes re-
mains questionable. It has been shown in some trials
that a reduction in HRV is associated with an in-
crease in the risk of mortality due to cardiovascular
diseases and overall mortality. One thing is certain:
long-term controlled studies with different statins are
needed to establish the role of HMG-CoA reductase
inhibitors as additional treatment for patients with
hypertension.
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